Amicus Therapeutics (NASDAQ:FOLD) Upgraded to “Buy” at StockNews.com

StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a hold rating to a buy rating in a report released on Saturday.

Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald raised their price objective on shares of Amicus Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Bank of America raised their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, October 17th. Jefferies Financial Group initiated coverage on shares of Amicus Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $18.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. Finally, Guggenheim raised their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $17.63.

Amicus Therapeutics Trading Down 0.2 %

Shares of NASDAQ:FOLD opened at $9.66 on Friday. Amicus Therapeutics has a 12 month low of $9.02 and a 12 month high of $14.57. The company has a quick ratio of 2.42, a current ratio of 3.15 and a debt-to-equity ratio of 2.18. The company’s fifty day simple moving average is $10.96 and its 200 day simple moving average is $10.61. The firm has a market cap of $2.89 billion, a price-to-earnings ratio of -28.41 and a beta of 0.68.

Insider Activity at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,901 shares of Amicus Therapeutics stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $11,083,175. This trade represents a 0.88 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Over the last 90 days, insiders sold 30,401 shares of company stock valued at $352,038. Corporate insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of FOLD. SG Americas Securities LLC bought a new position in shares of Amicus Therapeutics in the 1st quarter valued at about $291,000. Swiss National Bank grew its position in shares of Amicus Therapeutics by 2.3% in the 1st quarter. Swiss National Bank now owns 434,300 shares of the biopharmaceutical company’s stock valued at $5,116,000 after acquiring an additional 9,900 shares during the period. Sei Investments Co. grew its position in shares of Amicus Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 222,715 shares of the biopharmaceutical company’s stock valued at $2,624,000 after acquiring an additional 19,366 shares during the period. ProShare Advisors LLC grew its position in shares of Amicus Therapeutics by 10.7% in the 1st quarter. ProShare Advisors LLC now owns 72,845 shares of the biopharmaceutical company’s stock valued at $858,000 after acquiring an additional 7,068 shares during the period. Finally, Orion Portfolio Solutions LLC boosted its holdings in shares of Amicus Therapeutics by 9.0% during the 1st quarter. Orion Portfolio Solutions LLC now owns 152,187 shares of the biopharmaceutical company’s stock worth $1,793,000 after buying an additional 12,559 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.